Gantenerumab

Phase 2/3Terminated

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alzheimers Disease

Conditions

Alzheimers Disease, Dementia, Alzheimers Disease, Familial

Trial Timeline

Jun 3, 2020 → Nov 13, 2023

NCT ID

NCT06424236

About Gantenerumab

Gantenerumab is a phase 2/3 stage product being developed by Roche for Alzheimers Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT06424236. Target conditions include Alzheimers Disease, Dementia, Alzheimers Disease, Familial.

What happened to similar drugs?

0 of 5 similar drugs in Alzheimers Disease were approved

Approved (0) Terminated (1) Active (4)

🔄TrontinemabRochePhase 3

❌Gantenerumab + PlaceboRochePhase 3

🔄Semaglutide + PlaceboNovo NordiskPhase 3

🔄buntanetap/posiphen + PlaceboAnnovis BioPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04592341	Phase 2	Terminated	Nov 18, 2020	Mar 15, 2023	Alzheimer Disease
NCT06424236	Phase 2/3	Terminated	Jun 3, 2020	Nov 13, 2023	Alzheimers Disease
NCT04339413	Phase 3	Terminated	May 22, 2020	Jan 4, 2023	Alzheimer Disease
NCT03236844	Phase 1	Completed	Aug 1, 2017	Dec 15, 2017	Healthy Participants
NCT00531804	Phase 1	Completed	Dec 1, 2006	Sep 1, 2010	Alzheimer's Disease

Competing Products

15 competing products in Alzheimers Disease

See all competitors

Product	Company	Stage	Hype Score
E2814 + Lecanemab + Matching Placebo (E2814)	Eisai	Phase 2/3	42
Gantenerumab + Solanezumab + Matching Placebo (Gantenerumab) + Matching Placebo (Solanezumab) + Gantenerumab + E2814 + Lecanemab + Matching Placebo (E2814)	Eisai	Phase 2/3	42
Gantenerumab + Solanezumab + Matching Placebo (Gantenerumab) + Matching Placebo (Solanezumab)	Eli Lilly	Phase 2/3	38
Remternetug + Matching Placebo (Remternetug)	Eli Lilly	Phase 2/3	45
Remternetug (SC) + Matching Placebo (Remternetug)	Eli Lilly	Phase 2/3	45
CNP520 50mg + CNP520 15mg	Novartis	Phase 2/3	30
CAD106 Immunotherapy + CNP520	Novartis	Phase 2/3	30
Trontinemab	Roche	Phase 3	47
RO7126209 + Placebo	Roche	Phase 1	29
RO7126209 + Placebo	Roche	Phase 1/2	36
Trontinemab	Roche	Phase 3	47
Gantenerumab + Placebo	Roche	Phase 3	32
Semaglutide + Placebo	Novo Nordisk	Phase 3	40
X/T + X-EC + Placebo + Lecanemab 10 mg/kg	Bristol Myers Squibb	Phase 2	42
buntanetap/posiphen + Placebo	Annovis Bio	Phase 3	37